Acne Treatment: The Evidence-Based Ladder From Topicals to Isotretinoin

Acne vulgaris is the most common skin disease in the United States, affecting up to 50 million Americans annually. It is the primary reason patients seek care from dermatologists. Despite its prevalence, patients are often overwhelmed by conflicting marketing claims, social media trends, and complex medical treatment options.

To achieve clear skin safely, treatment should follow a structured, evidence-based ladder. In Jan 2024, the American Academy of Dermatology (AAD) published its updated Guidelines of Care for the Management of Acne Vulgaris in the Journal of the American Academy of Dermatology (JAAD). This document outlines 18 evidence-based recommendations and 5 good practice statements, establishing a clear treatment ladder.

For patients looking for a direct answer: treat acne stepwise: start with a topical retinoid + benzoyl peroxide (± topical antibiotic), escalate to a short oral antibiotic course or hormonal therapy if needed, and reserve oral isotretinoin for severe/scarring/treatment-resistant acne under the FDA iPLEDGE REMS — per the AAD 2024 guideline.

This guide translates the clinical recommendations of the AAD 2024 guideline into a patient-facing treatment ladder. It covers multimodal topicals, oral antibiotic stewardship, hormonal therapies, and the February 2026 FDA-approved modifications to the iPLEDGE program for isotretinoin (note: implementation was subsequently delayed to November 2026).

---

The Acne Treatment Ladder at a Glance

The AAD 2024 guideline emphasizes that acne is a complex, multifactorial disease that is best treated using combinations of medications targeting different pathological pathways (follicular hyperkeratinization, sebum production, Cutibacterium acnes colonization, and inflammation).

          [STEP 4: Oral Isotretinoin (Accutane + iPLEDGE REMS)]
                                ▲
                                │ (For severe, scarring, or resistant acne)
          [STEP 3: Hormonal Therapy (Women Only) OR Systemic Therapy]
                                ▲
                                │ (If topicals fail to control moderate acne)
          [STEP 2: Oral Antibiotics + Multimodal Topicals]
                                ▲
                                │ (Limited to 3-4 months to prevent resistance)
          [STEP 1: Multimodal Topical Therapy (Retinoid + BPO)]

---

What Is the First-Line Acne Treatment (and Why Multimodal Topicals)?

For mild to moderate acne, the AAD 2024 guideline strongly recommends starting with multimodal topical therapy. This means combining multiple topical active ingredients rather than relying on a single drug (monotherapy).

The gold standard first-line combination is:

1. A Topical Retinoid: To normalize skin cell shedding inside the pore (preventing comedones).
2. Benzoyl Peroxide (BPO): An antimicrobial agent that kills C. acnes bacteria through oxidation and helps break up dead skin cells.

The FDA-Approved Topical Retinoids

Topical retinoids are the foundation of acne therapy. The AAD 2024 guideline recognizes four FDA-approved topical retinoids for acne. The clinical data do not suggest the superiority of one agent over another; selection depends on patient tolerance, skin type, and cost:

• Tretinoin (Retin-A, Altreno): The most widely studied retinoid. Available in multiple strengths (0.025%, 0.05%, 0.1%) and vehicles (cream, gel, polymeric lotion). Newer formulations like Altreno (0.05% lotion) incorporate moisturizing bases to minimize irritation.
• Adapalene (Differin): A third-generation synthetic retinoid. It is more photostable than tretinoin, meaning it can be applied in the morning and combined with benzoyl peroxide without degrading. Adapalene 0.1% gel is available over-the-counter (OTC), while 0.3% remains prescription-only.
• Tazarotene (Tazorac, Arazlo): A highly potent retinoid. Often reserved for stubborn, comedonal acne or patients who also have significant acne scarring. Tazorac can be highly irritating, but newer micro-emulsion formulations (Arazlo 0.045%) offer improved tolerability.
• Trifarotene (Aklief): A fourth-generation retinoid that selectively targets the retinoic acid receptor (RAR)-gamma, which is highly expressed in the skin. It is approved for both facial and truncal (chest/back) acne and has a favorable safety and irritation profile.

To understand the difference between cosmetic over-the-counter retinoids and medical-grade prescriptions, read the retinol vs tretinoin comparison.

The Rule Against Antibiotic Monotherapy

If acne has an inflammatory component (red papules and pustules), the doctor may prescribe a topical antibiotic, such as clindamycin 1% or erythromycin 2%.

However, the AAD guideline issues a strong recommendation against using topical antibiotics alone. C. acnes bacteria adapt rapidly to antibiotics. If clindamycin is used as monotherapy, the bacteria become resistant within weeks, rendering the treatment useless and contributing to global antibiotic resistance.

To prevent resistance, topical antibiotics must always be combined with benzoyl peroxide. Benzoyl peroxide kills bacteria via a non-specific oxidative pathway to which C. acnes cannot develop resistance. Fixed-dose combination gels (such as clindamycin/benzoyl peroxide or adapalene/benzoyl peroxide) simplify the routine and improve patient compliance.

---

When Do Oral Antibiotics Fit, and How Long Is Safe?

For moderate to severe inflammatory acne that does not respond to topical therapy alone, the AAD 2024 guideline strongly recommends escalating to oral antibiotics combined with topical retinoids and benzoyl peroxide.

The preferred oral antibiotics are tetracycline derivatives:

• Doxycycline: The clinical first choice. It targets C. acnes and has anti-inflammatory properties that reduce swelling and redness. It is typically prescribed at 50 mg to 100 mg twice daily, or as a sub-antimicrobial dose (40 mg delayed-release daily) to minimize gut microbiome disruption.
• Minocycline: Highly effective but carries a slightly higher risk of rare side effects, including drug-induced lupus, hyperpigmentation of the skin/teeth, and vestibular issues (dizziness).
• Sarecycline (Seysara): A narrow-spectrum tetracycline designed to target C. acnes specifically while sparing gut bacteria, reducing gastrointestinal side effects.

The Principles of Antibiotic Stewardship in Acne Care

Due to the rise of antibiotic-resistant bacterial strains, the AAD guideline establishes strict limits on the use of systemic antibiotics:

1. Strict Duration Limits: Systemic antibiotics should be limited to the shortest duration possible, typically no longer than 3 to 4 months. They are meant to act as a temporary "bridge" to control inflammation while topical retinoids begin to work, not as a long-term maintenance therapy.
2. No Antibiotic Monotherapy: Just like topicals, oral antibiotics must never be used alone. They must always be paired with a topical retinoid (to treat the underlying follicular plugging) and benzoyl peroxide (to prevent systemic bacterial resistance).
3. No Swapping Antibiotics: If a patient's acne flares after completing an antibiotic course, the clinician should not cycle them onto a different oral antibiotic. Instead, they should evaluate the patient for alternative systemic therapies, such as hormonal agents or oral isotretinoin.

---

Hormonal Acne: Do Spironolactone and Birth Control Work?

For female patients whose acne flares cyclically along the lower face, jawline, and neck, the AAD 2024 guideline conditionally recommends hormonal therapy as an alternative to systemic antibiotics. Hormonal treatments target the androgen receptors in the sebaceous glands, reducing sebum (oil) production at the source.

Androgen Hormones ──> Stimulate Sebaceous Glands ──> Excess Sebum (Oil) Production
  ├── Combined Oral Contraceptives ──> Increase SHBG, lower free testosterone
  └── Spironolactone               ──> Competitively block androgen receptors

1. Spironolactone

Spironolactone is a potassium-sparing diuretic traditionally used for cardiovascular disease. Because it competitively blocks androgen receptors and inhibits 5-alpha reductase (the enzyme that converts testosterone to its more potent form, DHT), it is widely prescribed off-label for female acne.

• Clinical Efficacy: Typically prescribed at 50 mg to 150 mg daily. The AAD 2024 guideline gives spironolactone a conditional recommendation (moderate-quality evidence) for acne, backed by multiple clinical trials showing it achieves comparable clearance rates to oral doxycycline without antibiotic resistance risks.
• Safety Profile: Spironolactone is safe for long-term use. Common side effects include frequent urination, breast tenderness, irregular menstrual cycles, and blood pressure fluctuations. While traditionally clinicians checked blood potassium levels periodically, current consensus holds that potassium monitoring is unnecessary in healthy young women with normal kidney function.
• Contraindication: Spironolactone can cause feminization of a male fetus. Women taking it must use effective contraception to prevent pregnancy.

2. Combined Oral Contraceptives (COCs)

The AAD conditionally recommends FDA-approved combined oral contraceptives containing both estrogen and progesterone. The estrogen component increases Sex Hormone-Binding Globulin (SHBG), which binds free testosterone in the blood, reducing the amount of androgen available to stimulate oil glands.

There are currently four COCs FDA-approved for acne:

• Ortho Tri-Cyclen (norgestimate/ethinyl estradiol)

• Estrostep (norethindrone acetate/ethinyl estradiol)

• Yaz (drospirenone/ethinyl estradiol)

• Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium)

• Clinical Notes: COCs take 3 to 6 months to show significant acne clearance. They are often combined with spironolactone for synergistic effects. They should not be prescribed to women with a history of deep vein thrombosis (DVT), cardiovascular disease, uncontrolled hypertension, or those over 35 who smoke.

3. Innovative Topical Pathways: Clascoterone (Winlevi)

A significant milestone in acne pharmacology is the approval of clascoterone 1% cream (Winlevi). It represents the first new mechanism of action in topical acne treatment approved by the FDA in nearly 40 years.

Clascoterone is a topical androgen receptor inhibitor. It competes directly with dihydrotestosterone (DHT) at the androgen receptors within the sebaceous glands and hair follicles. By blocking these receptors, it reduces sebum production and decreases the synthesis of inflammatory cytokines.

• Indication: It is FDA-approved for both male and female patients aged 12 and older with acne vulgaris. Unlike oral spironolactone, which is strictly limited to females due to systemic anti-androgenic side effects (such as gynecomastia and feminization of male fetuses), topical clascoterone has negligible systemic absorption and can be safely used by males without hormonal side effects.
• Clinical Application: Applied twice daily to clean, dry skin. It fits neatly as an adjunct to topical retinoid therapy.

The Role of Physical and Laser Modalities in Acne Clearance

While pharmacotherapy remains the first-line clinical standard, physical and energy-based modalities play a supportive role in the AAD 2024 guidelines:

• Chemical Peels: Peels using salicylic acid (20% to 30%) or glycolic acid promote rapid exfoliation, unclog pores, and help resolve post-inflammatory hyperpigmentation. They are recommended as adjunct therapies to hasten clearance but are not substitutes for baseline topicals.
• Light and Laser Therapies: Photodynamic therapy (PDT) and blue/red light devices target C. acnes bacteria and temporarily reduce inflammation. The AAD guideline gives a conditional recommendation for these physical treatments, noting that while they offer short-term benefits, evidence for long-term clearance is limited compared to systemic pharmacotherapy. For patients seeking a device-only path, advanced 1726 nm sebaceous-gland-selective lasers offer a promising option.

---

Isotretinoin (Accutane): Who Needs It, How It Works, and the iPLEDGE Rules

For patients with severe, nodulocystic acne, acne that leaves permanent physical scars, or moderate acne that fails standard therapy and causes severe psychosocial distress, the AAD 2024 guideline issues a strong recommendation for oral isotretinoin (formerly branded as Accutane, now available as Claravis, Amnesteem, Myorisan, and Absorica).

Isotretinoin is a systemic retinoid that targets all four pathogenic pathways of acne. It permanently shrinks the sebaceous glands, reducing oil production by up to 90%, normalizes cell shedding, reduces bacterial colonization, and halts inflammation. A typical treatment course runs 4 to 6 months and achieves long-term remission in approximately 70% to 80% of patients.

The Clinical Safety and Monitoring Protocol

Due to its potency, oral isotretinoin requires careful clinical supervision:

• Dosing: Initiated at a low dose (0.5 mg/kg/day) and titrated up to 1.0 mg/kg/day to reach a target cumulative dose of 120 to 150 mg/kg, which is associated with lower relapse rates. Newer lipid-encapsulated formulations (Absorica) can be taken without food, whereas traditional formulations must be taken with a high-fat meal to ensure absorption.
• Lab Monitoring: The AAD guideline recommends baseline blood tests for liver enzymes (AST/ALT) and fasting lipids (cholesterol and triglycerides), with a repeat test at 4 to 8 weeks. Routine monthly testing is no longer recommended for healthy patients whose early labs are normal.

The FDA iPLEDGE REMS Program

Isotretinoin is a powerful teratogen, meaning exposure during pregnancy causes severe birth defects, miscarriage, or fetal death. To prevent fetal exposure, the FDA mandates enrollment in the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS).

Current iPLEDGE Requirements (In Effect Now)

For patients who can become pregnant, these requirements apply under the program as it operates today:

1. Dual Contraception: Must commit to using two forms of effective contraception (e.g., an IUD plus condoms) starting 1 month before treatment, during the entire course, and for 1 month after discontinuing the drug.
2. Pregnancy Testing: Must undergo monthly pregnancy tests.
3. Strict 7-Day Window: Prescriptions must be filled and picked up within a strict 7-day window from the date of the pregnancy test.

What Is Changing with iPLEDGE (Approved Feb 2026 — Not Yet In Effect)

On February 9, 2026, the FDA approved significant modifications to the iPLEDGE REMS program to reduce administrative burdens and improve patient access. The changes were originally scheduled to take effect about 180 days later (~August 8, 2026), but on June 16, 2026, the FDA announced that implementation is delayed until November 15, 2026 to allow additional time to test system updates. As of July 2026, the current iPLEDGE requirements above remain fully in effect, and the FDA is exercising enforcement discretion until the new effective date. The approved (but not yet active) modifications are:

• At-Home Pregnancy Testing: Once effective, patients who can get pregnant will be permitted to perform their monthly pregnancy tests at home using approved test kits and report results through a patient portal, rather than requiring in-office lab draws. Note: The initial pre-treatment pregnancy test must still be performed in a clinical setting.
• Removal of the 19-Day Lockout: Historically, if a patient missed their 7-day prescription pick-up window, they were locked out of the system for 19 days. The modification will eliminate this lockout, allowing the patient to re-test and obtain a new prescription without the wait.
• Removal of Monthly Counseling Documentation: Will remove the requirement for the prescribing doctor to log in to the portal and document monthly counseling before the pharmacy can dispense the drug.
• Removal of the 30-Day Window for Male/Non-Pregnant Patients: Patients who cannot get pregnant will no longer be bound by a 30-day prescription expiration window, simplifying refills.

---

How Long Until Acne Treatment Works, and What About Scarring and PIH?

Patience is a critical component of acne management. Skin cells take approximately 28 to 30 days to cycle, and medications require time to clear existing blockages and prevent new lesions from forming.

The table below outlines the realistic clinical timelines for initial response and peak efficacy across the acne ladder:

Managing Post-Acne Sequelae: PIH, Redness, and Scars

As active acne lesions resolve, they often leave behind temporary marks or permanent changes in skin texture:

1. Post-Inflammatory Hyperpigmentation (PIH): Dark brown or black flat marks left behind by healed acne, particularly common in skin of color (Fitzpatrick types IV–VI). Topical retinoids and chemical peels are highly effective at accelerating pigment clearance. For safe clinical protocols on managing PIH, read the post-inflammatory hyperpigmentation guide.
2. Post-Inflammatory Erythema (PIE): Pink or red flat marks caused by dilated capillaries during inflammation. These respond well to vascular lasers, such as pulsed dye lasers (Vbeam) or Excel V, and gentle barrier-repairing topicals.
3. Atrophic Acne Scars: Permanent depressions in the skin (icepick, boxcar, or rolling scars) caused by the loss of collagen during severe nodular inflammation. These cannot be resolved with topical skincare and require physical procedures like microneedling, subcision, TCA CROSS, or fractional lasers once the active acne is completely controlled. For an analysis of treatments tailored to darker skin types, refer to the acne scar treatments reference.
4. Device-Based Options for Active Acne: In addition to medications, physical modalities like the AviClear 1726nm laser offer an alternative by targeting the sebaceous glands directly. For a clinical analysis of this technology, read the AviClear 1726nm laser review.

---

FAQs

Can I use benzoyl peroxide and a retinoid at the same time?

It depends on the formulation. Traditional prescription tretinoin is unstable and degrades when exposed to benzoyl peroxide or light, meaning they must be applied at different times (BPO in the morning, tretinoin at night). However, adapalene (Differin) and tazarotene are chemically stable and can be applied together. Modern fixed-dose combination prescriptions (such as Epiduo, which combines adapalene and benzoyl peroxide) are engineered to be stable and are applied once daily at night.

Does diet (dairy, sugar, whey) cause acne?

Diet does not cause acne on its own, but it can exacerbate it in predisposed individuals. The AAD 2024 guideline notes that high-glycemic-load diets (foods that cause rapid blood sugar spikes, like white bread, sugary drinks, and processed snacks) and dairy products (particularly skim milk and whey protein supplements) can increase insulin-like growth factor-1 (IGF-1), which stimulates sebum production and inflammation. Modifying diet may be a helpful supportive measure, but it is not a substitute for standard medical therapy.

How bad are isotretinoin side effects, and does it cause depression?

Isotretinoin causes dose-dependent side effects. The most common are dry lips (cheilitis), dry skin, dry eyes, and nosebleeds. These affect virtually 100% of patients and are managed with thick moisturizers, lip balms, and artificial tears. Muscle aches and mild joint pain can also occur. Regarding mental health, while historical reports linked isotretinoin to depression and suicidal ideation, large-scale epidemiological studies have not proven a causal relationship; in fact, successful acne clearance often improves depression and anxiety. However, the FDA retains a warning on the label, and patients with a history of psychiatric illness should be closely monitored.

What changed with iPLEDGE in 2026?

On February 9, 2026, the FDA approved modifications to the iPLEDGE REMS program. They were originally set to take effect around August 8, 2026, but the FDA announced on June 16, 2026 that implementation is delayed until November 15, 2026 to allow more time for system testing. Until then, the current iPLEDGE rules remain in effect. Once active, the changes will allow patients who can get pregnant to perform monthly pregnancy tests at home and report them online; remove the 19-day lockout if a patient misses their 7-day prescription window; remove the requirement for doctors to document monthly counseling in the portal; and remove the 30-day prescription window for male and non-pregnant patients.

When should I see a dermatologist instead of treating acne myself?

You should consult a board-certified dermatologist if:

• Your acne does not improve after 6 to 12 weeks of consistent use of over-the-counter products (like adapalene 0.1% and benzoyl peroxide).
• Your acne is severe, painful, and characterized by deep nodules or cysts.
• Your acne is leaving permanent scars (depressions or raised bumps) or long-lasting dark spots (PIH).
• Your acne is causing significant psychological distress, social withdrawal, or anxiety.

For tips on finding a qualified clinical provider, read the guide on how to choose a provider.

---

Sources

• Reynolds, R. V., et al. (2024). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 90(5), 1006–1022. https://doi.org/10.1016/j.jaad.2023.12.017
• U.S. Food and Drug Administration. (2026). iPLEDGE Risk Evaluation and Mitigation Strategy (REMS); FDA alert: implementation of iPLEDGE REMS modifications delayed until November 15, 2026 (announced June 16, 2026). Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge-risk-evaluation-and-mitigation-strategy-rems
• U.S. Food and Drug Administration. (2010). iPLEDGE REMS Document (accessdata.fda.gov). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018662s061REMS.pdf
• Guideline Central. (2024). AAD Guidelines of Care for the Management of Acne Vulgaris Summary. Retrieved from https://www.guidelinecentral.com/guideline/21839
• American Academy of Family Physicians. (2017). Acne Vulgaris: Treatment Guidelines from the AAD. American Family Physician, 95(11), 740-741. Retrieved from https://www.aafp.org/afp/2017/0601/p740
• MedPage Today. (2024). New Acne Guidelines Sift Through Topicals, Hormonal Rx, and Isotretinoin. Retrieved from https://www.medpagetoday.com/dermatology/generaldermatology/108745